Research/art/teacher profile of a person
Name and surname:
PharmDr. Gabriel Dóka, PhD.
Document type:
Research/art/teacher profile of a person
The name of the university:
Comenius University Bratislava
The seat of the university:
Šafárikovo námestie 6, 818 06 Bratislava

I. - Basic information

I.1 - Surname
Dóka
I.2 - Name
Gabriel
I.3 - Degrees
PharmDr., PhD.
I.4 - Year of birth
1985
I.5 - Name of the workplace
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University Bratislava
I.6 - Address of the workplace
Comenius University Bratislava, Faculty of Pharmacy, Odbojárov 10, SK-832 32 Bratislava 3, Slovak Republic
I.7 - Position
Assistant professor
I.8 - E-mail address
doka@fpharm.uniba.sk
I.9 - Hyperlink to the entry of a person in the Register of university staff
https://www.portalvs.sk/regzam/detail/23053
I.10 - Name of the study field in which a person works at the university
Pharmacy

II. - Higher education and further qualification growth

II.1 - First degree of higher education
II.2 - Second degree of higher education
II.a - Name of the university or institution
Faculty of Pharmacy, Comenius University Bratislava
II.b - Year
2010
II.c - Study field and programme
Pharmacy
II.3 - Third degree of higher education
II.a - Name of the university or institution
Faculty of Pharmacy, Comenius University Bratislava
II.b - Year
2016
II.c - Study field and programme
Pharmacology
II.4 - Associate professor
II.5 - Professor
II.6 - Doctor of Science (DrSc.)

III. - Current and previous employment

III.a - Occupation-position III.b - Institution III.c - Duration
Assistant professor Faculty of Pharmacy, Comenius University Bratislava 1.9.2014 -
Assistant professor Faculty of Medicine, Slovak Medical University in Bratislava 15.2.2021 -

IV. - Development of pedagogical, professional, language, digital and other skills

IV.a - Activity description, course name, other IV.b - Name of the institution IV.c - Year
Protection of animals used for scientific or educational purposes Institute of Postgraduate Education of Veterinary Surgeons 2023
Scientific qualification level IIa Commission of SAS for assessing the academic qualification of employees 2020

V. - Overview of activities within the teaching career at the university

V.1 - Overview of the profile courses taught in the current academic year according to study programmes
V.1.a - Name of the profile course V.1.b - Study programme V.1.c - Degree V.1.d - Field of study
Pharmacology Pharmacy 1.+2. Pharmacy
Clinical Pharmacy Pharmacy 3. Clinical Pharmacy
V.2 - Overview of the responsibility for the delivery, development and quality assurance of the study programme or its part at the university in the current academic year
V.3 - Overview of the responsibility for the development and quality of the field of habilitation procedure and inaugural procedure in the current academic year
V.4 - Overview of supervised final theses
V.4.1 - Number of currently supervised theses
V.4.a - Bachelor's (first degree)
0
V.4.b - Diploma (second degree)
4
V.4.c - Dissertation (third degree)
1
V.4.2 - Number of defended theses
V.4.a - Bachelor's (first degree)
1
V.4.b - Diploma (second degree)
16
V.4.c - Dissertation (third degree)
0
V.5 - Overview of other courses taught in the current academic year according to study programmes
V.5.a - Name of the course V.5.b - Study programme V.5.c - Degree V.5.d - Field of study
Clinical Pharmacology and Pharmacotherapy Pharmacy 1.+2. Pharmacy
Basics of Pharmacology Medical and Diagnostic Devices 1. Healthcare Sciences
Clinical Pharmacy and Pharmacotherapy Pharmacy 1.+2. Pharmacy
Toxicology Pharmacy 1.+2. Pharmacy
Analytical monitoring of drug levels in practice Pharmacy 1.+2. Pharmacy

VI. - Overview of the research/artistic/other outputs

VI.1 - Overview of the research/artistic/other outputs and the corresponding citations
VI.1.1 - Number of the research/artistic/other outputs
VI.1.a - Overall
126
VI.1.b - Over the last six years
49
VI.1.2 - Number of the research/artistic/other outputs registered in the Web of Science or Scopus databases
VI.1.a - Overall
21
VI.1.b - Over the last six years
12
VI.1.3 - Number of citations corresponding to the research/artistic/other outputs
VI.1.a - Overall
133
VI.1.b - Over the last six years
77
VI.1.4 - Number of citations registered in the Web of Science or Scopus databases
VI.1.a - Overall
133
VI.1.b - Over the last six years
77
VI.1.5 - Number of invited lectures at the international, national level
VI.1.a - Overall
3
VI.1.b - Over the last six years
3
VI.2 - The most significant research/artistic/other outputs
1

Doka G, Malikova E, Galkova K, La Rocca G, Kruzliak P, Adamek M, Rodrigo L, Krenek P, Klimas J. Downregulation of myogenic microRNAs in sub-chronic but not in sub-acute model of daunorubicin-induced cardiomyopathy. Mol Cell Biochem. 2017 Aug;432(1-2):79-89. doi: 10.1007/s11010-017-2999-8. Epub 2017 Mar 16. PMID: 28303410.

2

Cernecka H, Doka G, Srankova J, Pivackova L, Malikova E, Galkova K, Kyselovic J, Krenek P, Klimas J. Ramipril restores PPARβ/δ and PPARγ expressions and reduces cardiac NADPH oxidase but fails to restore cardiac function and accompanied myosin heavy chain ratio shift in severe anthracycline-induced cardiomyopathy in rat. Eur J Pharmacol. 2016 Nov 15;791:244-253. doi: 10.1016/j.ejphar.2016.08.040. Epub 2016 Aug 31. PMID: 27592051.

3

Kmecova Z, Veteskova J, Lelkova-Zirova K, Bies Pivackova L, Doka G, Malikova E, Paulis L, Krenek P, Klimas J. Disease severity-related alterations of cardiac microRNAs in experimental pulmonary hypertension. J Cell Mol Med. 2020 Jun;24(12):6943-6951. doi: 10.1111/jcmm.15352. Epub 2020 May 12. PMID: 32395887; PMCID: PMC7299706.

VI.3 - The most significant research/artistic/other outputs over the last six years
1

Doka G, Malikova E, Galkova K, La Rocca G, Kruzliak P, Adamek M, Rodrigo L, Krenek P, Klimas J. Downregulation of myogenic microRNAs in sub-chronic but not in sub-acute model of daunorubicin-induced cardiomyopathy. Mol Cell Biochem. 2017 Aug;432(1-2):79-89. doi: 10.1007/s11010-017-2999-8. Epub 2017 Mar 16. PMID: 28303410.

2

Kmecova Z, Veteskova J, Lelkova-Zirova K, Bies Pivackova L, Doka G, Malikova E, Paulis L, Krenek P, Klimas J. Disease severity-related alterations of cardiac microRNAs in experimental pulmonary hypertension. J Cell Mol Med. 2020 Jun;24(12):6943-6951. doi: 10.1111/jcmm.15352. Epub 2020 May 12. PMID: 32395887; PMCID: PMC7299706.

3

Nemcekova V, Kmecova Z, Bies Pivackova L, Goncalvesova E, Krenek P, Doka G, Klimas J. Hematocrit-Related Alterations of Circulating microRNA-21 Levels in Heart Failure Patients with Reduced Ejection Fraction: A Preliminary Study. Genet Test Mol Biomarkers. 2021 Apr;25(4):302-306. doi: 10.1089/gtmb.2020.0277. PMID: 33877895.

VI.4 - The most significant citations corresponding to the research/artistic/other outputs
1

Skála M, Hanousková B, Skálová L, Matoušková P. MicroRNAs in the diagnosis and prevention of drug-induced cardiotoxicity. Arch Toxicol. 2019 Jan;93(1):1-9. doi: 10.1007/s00204-018-2356-z. Epub 2018 Nov 20. PMID: 30460422.

2

Santos D, Carvalho E. Adipose-related microRNAs as modulators of the cardiovascular system: the role of epicardial adipose tissue. J Physiol. 2022 Mar;600(5):1171-1187. doi: 10.1113/JP280917. Epub 2021 Sep 16. PMID: 34455587.

3

Jarabicová I, Horváth C, Veľasová E, Bies Piváčková L, Vetešková J, Klimas J, Křenek P, Adameová A. Analysis of necroptosis and its association with pyroptosis in organ damage in experimental pulmonary arterial hypertension. J Cell Mol Med. 2022 May;26(9):2633-2645. doi: 10.1111/jcmm.17272. Epub 2022 Apr 7. PMID: 35393789; PMCID: PMC9077306.

4

Amsallem M, Sweatt AJ, Arthur Ataam J, Guihaire J, Lecerf F, Lambert M, Ghigna MR, Ali MK, Mao Y, Fadel E, Rabinovitch M, de Jesus Perez V, Spiekerkoetter E, Mercier O, Haddad F, Zamanian RT. Targeted proteomics of right heart adaptation to pulmonary arterial hypertension. Eur Respir J. 2021 Apr 8;57(4):2002428. doi: 10.1183/13993003.02428-2020. PMID: 33334941; PMCID: PMC8029214.

VI.5 - Participation in conducting (leading) the most important research projects or art projects over the last six years
1

VEGA 1/0304/17: The role of HCN channels in the development of diabetic cardiomyopathy and related changes in myocardial electrogenesis.

Deputy Principal Investigator

2

VEGA 1/0195/20: The role of hepatocyte growth factor in the onset and progression of diabetic cardiomyopathy.

Deputy Principal Investigator

3

APVV-15-0685: Teranostic potential of alternative RAS components in modulation of right ventricular function and dysfunction

Co-investigator


4

APVV-0887-11: Molecular aspects of drug-induced heart failure and ventricular arrhythmias

Co-investigator

VII. - Overview of organizational experience related to higher education and research/artistic/other activities

VIII. - Overview of international mobilities and visits oriented on education and research/artistic/other activities in the given field of study

VIII.a - Name of the institution VIII.b - Address of the institution VIII.c - Duration (indicate the duration of stay) VIII.d - Mobility scheme, employment contract, other (describe)
Institut für Pharmakologie und Toxikologie Westfälische Wilhelms-Universität Münster, Germany 1.8.2014 - 31.8.2014
Charles University in Prague, Czech Republic, Faculty of Pharmacy Hradec Králové, Česká republika 17.10.2022 - 22.10.2022 BIP Erasmus Course “European course on population ageing, development of geriatric clinical pharmacy services and research activities in deprescribing”
Faculty of Pharmacy, University of Ljubljana Ljubljana, Slovenia 12. 2. 2024 - 16. 02. 2024 STT Erasmus+ mobility with a focus on the development of pedagogical skills and curriculum design in the subject Pharmacogenetics

IX. - Other relevant facts

IX.a - If relevant, other activities related to higher education or research/artistic/other activities are mentioned
  1. Expert guarantor of the interdisciplinary nationwide project "Clinical Skills Event" under the auspices of the International Pharmaceutical Students ‘Federation (IPSF)
  2. Lecturer in the Specialized Study in the Specialized field of Pharmacy
  3. Member of the organizing committee of the international workshop: ESCP Spring Workshop 2024: Pharmacotherapy challenges in the developing years: from conception to adolescence.
  4. Supervisor of rigorous theses - number of defended rigorous theses = 7
Date of last update
2023-09-19